At Jazz, National Epilepsy Awareness Month serves as a crucial moment to recognize the importance of raising awareness for patients with severe forms of epilepsy, and how we at Jazz work to continuously provide support for patients and caregivers.

We believe all people, particularly those who live with complex conditions, deserve new and better therapeutic options, and for the approximately 37,000 adult patients who have been diagnosed with idiopathic hypersomnia and are actively seeking care, this launch is a sign of hope the population has yet to see.

In recognition of International Lennox-Gastaut Syndrome (LGS) Awareness Day, which takes place every year on November 1, we sat down with Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation, to discuss the importance of raising awareness of LGS – a developmental brain disorder that frequently evolves from early-life-onset epilepsy – and share her family’s personal journey with the disease.

By helping to bridge the gaps that can sometimes occur between academics and companies when conducting clinical translational research, the SU2C Catalyst program embodies the type of multisectoral partnerships that we at Jazz know are integral to addressing some of the largest hurdles in healthcare.

As part of our commitment to the cancer community, Jazz actively seeks out and listens to patients, physicians, care teams and advocacy groups for insights that could help develop new or better standards of care for rare and difficult-to-treat cancers.

This month, we have been uplifting the voices of our LGBTQ+ colleagues, educating allies on queer history and commemorating the spirit of resistance –and resilience –with which Pride began.